TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20207521

Group type: EXPERIMENTAL
Intervention: Topiramate (100mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Olanzapine + Placebo
Number of subjects: 72
Study: 17889449

Group type: EXPERIMENTAL
Intervention: Baseline FACT-H&N score
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Functional well-being component of FACT-H&N
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Patients without baseline FACT-H&N data
Number of subjects: 1093
Study: 15941977

Group type: EXPERIMENTAL
Intervention: 15 g of alcohol per day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 30 g of alcohol per day
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0 g of alcohol per day (control)
Number of subjects: 53
Study: 12090649

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard medical care alone (Control)
Number of subjects: 24
Study: 10339777

Group type: EXPERIMENTAL
Intervention: Etidronate therapy (400 mg/d for 14 days with 76-day intervals, plus 500 mg of supplemental calcium per day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Etidronate therapy
Number of subjects: 83
Study: 8954030

Group type: EXPERIMENTAL
Intervention: 1 mg aldosterone iv
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo iv
Number of subjects: 10
Study: 1709185

Group type: EXPERIMENTAL
Intervention: Pollen antigen (Ag)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Buffer (B) control
Number of subjects: 7
Study: 7028051

Group type: EXPERIMENTAL
Intervention: 1% ciclopiroxolamine solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% ciclopiroxolamine cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% tolnaftate solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% clotrimazole solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% clotrimazole cream
Number of subjects: 0
Study: 30887675

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 102
Study: 29392984

Group type: EXPERIMENTAL
Intervention: ECAS score
Number of subjects: 5010
Study: 26425793

Group type: EXPERIMENTAL
Intervention: Transfemoral transcatheter aortic valve replacement (TF‐TAVR)
Number of subjects: 1521
Study: 24812317

Group type: EXPERIMENTAL
Intervention: Positive reappraisal coping intervention (PRCI)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Emotional monitoring only
Number of subjects: 377

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 377
Study: 22092899

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cognitive exam
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both simulation and cognitive exam
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Passing the cognitive exam
Number of subjects: 107
Study: 19458430

Group type: EXPERIMENTAL
Intervention: Online Rivermead Behavioral Memory Test (OL-RBMT)
Number of subjects: 30
Study: 17350969

Group type: EXPERIMENTAL
Intervention: esmolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: remifentanil
Number of subjects: 30
Study: 14972467

Group type: EXPERIMENTAL
Intervention: Genistein-rich extract (3 capsules daily for 6 months)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Active surveillance (watchful waiting) subgroup
Number of subjects: 62
Study: 11869759

Group type: EXPERIMENTAL
Intervention: Depressive cluster (n=22)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Delusional cluster (n=39)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Classic cluster (n=72)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Irritable cluster (n=29)
Number of subjects: 162
Study: 9134943

Group type: EXPERIMENTAL
Intervention: Topical 1% penciclovir cream
Number of subjects: 2209

Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 2209
Study: 8198018

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin with cholestyramine
Number of subjects: 0
Study: 10302355

Group type: EXPERIMENTAL
Intervention: Sequential protocol using anti-lymphocyte serum (ALS) followed by cyclosporine from the third post-graft month onwards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment with ALS alone
Number of subjects: 0
Study: 30358132

Group type: EXPERIMENTAL
Intervention: African Dance
Number of subjects: 28

Group type: COMPARATOR
Intervention: Culture Education
Number of subjects: 28
Study: 27052286

Group type: EXPERIMENTAL
Intervention: Traditional Classroom Instruction (TCI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-Instructed Video (SIV)
Number of subjects: 80
Study: 25023098

Group type: COMPARATOR
Intervention: 9 mL agitated saline solution with 1 mL air without the Valsalva maneuver (ASwoVM)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 9 mL agitated saline solution with 1 mL air with the Valsalva maneuver (ASwVM)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 9 mL agitated saline solution, 1 mL air and a drop of the patient's blood without the Valsalva maneuver (ASbwoVM)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 9 mL agitated saline solution, 1 mL air and a drop of the patient's blood, with the Valsalva maneuver (ASbwVM)
Number of subjects: 330
Study: 22901712

Group type: EXPERIMENTAL
Intervention: CT-guided radiofrequency ablation (RFA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: MR-guided laser ablation (LA)
Number of subjects: 44
Study: 20596936

Group type: EXPERIMENTAL
Intervention: Tea filters used in cigarette filters for 2 months
Number of subjects: 0
Study: 17825122

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention (educational/CBT workbook, educational visit to consultants, reminder system on medication charts)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Guidelines alone (control group)
Number of subjects: 19
Study: 16107602

Group type: EXPERIMENTAL
Intervention: Hypercaloric feeding (1.8-fold of resting energy expenditure)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (1.2-fold of resting energy expenditure)
Number of subjects: 28
Study: 14595609

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for 6 months
Number of subjects: 52
Study: 10227804

Group type: EXPERIMENTAL
Intervention: 2 g IVIG/kg/month
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 g IVIG/kg/month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (2 g iv albumin/kg/month)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 40
Study: 8693937

Group type: EXPERIMENTAL
Intervention: Intensified information activities
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Condom use at first intercourse
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Condom use when changing partner
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Concerns about safety of oral contraceptives
Number of subjects: 275
Study: 1883670

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 at 30 ng/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epoprostenol at 5 ng/kg/min
Number of subjects: 20
Study: 6129459

Group type: COMPARATOR
Intervention: fenoprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhus tox. 6X
Number of subjects: 0
Study: 31653800

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum (QL) block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no block)
Number of subjects: 80
Study: 28127204

Group type: EXPERIMENTAL
Intervention: LAM + vaccine
Number of subjects: 225

Group type: COMPARATOR
Intervention: LAM + placebo
Number of subjects: 225
Study: 26265560

Group type: EXPERIMENTAL
Intervention: CPAP therapy with good adherence
Number of subjects: 73
Study: 25493316

Group type: EXPERIMENTAL
Intervention: Dermoscope
Number of subjects: 381

Group type: COMPARATOR
Intervention: Naked-eye examination (Control)
Number of subjects: 381
Study: 22467697

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (n = 83)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (n = 77)
Number of subjects: 160
Study: 19607951

Group type: EXPERIMENTAL
Intervention: Virosomal vaccine (Inflexal V)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard subunit vaccine (Influvac)
Number of subjects: 105
Study: 17542868

Group type: EXPERIMENTAL
Intervention: Go Sun Smart program
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control resorts
Number of subjects: 357
Study: 15109968

Group type: EXPERIMENTAL
Intervention: Histamine iontophoresis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Capsaicin-induced muscle pain
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline iontophoresis (placebo)
Number of subjects: 18
Study: 11233454

Group type: EXPERIMENTAL
Intervention: Time-phased patient education program (RHYTHMS)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care (no educational materials)
Number of subjects: 246
Study: 9686498

Group type: EXPERIMENTAL
Intervention: Patients with sarcoidosis (BAL fluid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with sarcoidosis (Peripheral blood)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (BAL fluid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients with sarcoidosis (BAL fluid vs Peripheral blood)
Number of subjects: 18
Study: 7852064

Group type: EXPERIMENTAL
Intervention: Low-dose group, 50 mg elemental iron + 60 mg ascorbic acid in a multi‐vitamin daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Usual-dose group, 200 mg elemental iron daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 128
Study: 2682011

Group type: EXPERIMENTAL
Intervention: Ringer's lactate solution plus 50 gm of albumin (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ringer's lactate solution alone (group B)
Number of subjects: 100
Study: 1253701

Group type: EXPERIMENTAL
Intervention: Combined preparation containing 250 mg clofibrate and 180 mg inositol nicotinate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clofibrate alone in double doses
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined preparation (doubled dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clofibate alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined preparation
Number of subjects: 14
Study: 29258812

Group type: EXPERIMENTAL
Intervention: 5 mg/kg bevacizumab with FOLFIRI
Number of subjects: 124

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 124
Study: 26661514

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 492

Group type: COMPARATOR
Intervention: Liraglutide 0.9 mg
Number of subjects: 492
Study: 25827011

Group type: EXPERIMENTAL
Intervention: Cytoflavin included in complex intensive care (starting from 2 days post-traumatic period)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard intensive care
Number of subjects: 39
Study: 22289674

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (H2RA) administered per os as a single dose immediately before surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI) administered in two oral doses (the night before and on the morning of surgery)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI) administered as a single intravenous infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: H2-receptor antagonists (H2RA) administered in two doses (the night before and on the morning of surgery)
Number of subjects: 18
Study: 20809746

Group type: EXPERIMENTAL
Intervention: Preoperative knee adduction moment during gait
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of implant type, preoperative knee joint loading patterns during gait, and body mass index
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Preoperative functional characteristics
Number of subjects: 37
Study: 19033601

Group type: EXPERIMENTAL
Intervention: G20 (20% maximal strength)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: G50 (50% maximal strength)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: G80 (80% maximal strength)
Number of subjects: 112

Group type: COMPARATOR
Intervention: CON (nontraining control group)
Number of subjects: 112
Study: 16575276

Group type: EXPERIMENTAL
Intervention: Weight reduction counselling
Number of subjects: 523

Group type: COMPARATOR
Intervention: No counselling
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Each additional counselling strategy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Counselled patients
Number of subjects: 523

Group type: COMPARATOR
Intervention: Not counselled patients
Number of subjects: 523
Study: 12874608

Group type: EXPERIMENTAL
Intervention: Valsartan (n=1899)
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Valsartan in combination with hydrochlorothiazide (n=276)
Number of subjects: 2202

Group type: COMPARATOR
Intervention: Conventional therapy (Control group, n=27)
Number of subjects: 2202
Study: 10984366

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (100 microg/actuation) plus salbutamol (100 microg/actuation) administered as 4 puffs every 20 minutes for 3 doses.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Salbutamol (100 microg/actuation) alone administered as 4 puffs every 20 minutes for 3 doses.
Number of subjects: 74
Study: 8560674

Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg/day for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicalutamide 100-200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicalutamide up to 450 mg daily
Number of subjects: 0
Study: 1832346

Group type: EXPERIMENTAL
Intervention: Dianette + 2 mg CPA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dianette + 20 mg CPA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dianette + 100 mg CPA
Number of subjects: 60
Study: 6418109

Group type: EXPERIMENTAL
Intervention: Lithium carbonate addition
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lithium carbonate addition in amitriptyline-pretreated patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lithium carbonate withdrawal
Number of subjects: 39
Study: 30617197

Group type: EXPERIMENTAL
Intervention: obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: activated B-cell-like (ABC) COO subtype
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: unclassified COO subtype
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: CNS-IPI-C model (high CNS-IPI and ABC/unclassified COO)
Number of subjects: 1418
Study: 30239561

Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3OHB) infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nonesterified fatty acids (Intralipid) infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study: 26991329

Group type: EXPERIMENTAL
Intervention: 30-min plasma glucose (30-min PG) tertiles: T1 < 9.1 mmol/L, T2 9.2-10.4 mmol/L, T3 ≥ 10.4 mmol/L
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: 30-min plasma glucose (30-min PG)
Number of subjects: 753
Study: 24913484

Group type: EXPERIMENTAL
Intervention: Energy drink (500 ml containing 160 mg of caffeine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Energy drink + Rest (500 ml of energy drink and 10 min rest after 100 min of driving)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo drink (500 ml)
Number of subjects: 15
Study: 22301126

Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 20467003

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 26
Study: 18047036

Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 15735265

Group type: EXPERIMENTAL
Intervention: Radiant warmer (Fisher & Paykel)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Forced air warmer (Augustine Medical)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Polyester filled blanket
Number of subjects: 8
Study: 11880561

Group type: EXPERIMENTAL
Intervention: Oat consumption (14 g/d of dietary fiber, 5.5 g beta-glucan)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wheat cereals (14 g/d of dietary fiber, no beta-glucan)
Number of subjects: 36
Study: 10193912

Group type: EXPERIMENTAL
Intervention: Caregivers
Number of subjects: 191

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 191
Study: 8566890

Group type: EXPERIMENTAL
Intervention: Single-donor fresh frozen plasma (FFP) substitution, total of 42 doses at a median of 10 (5-20) mliter/kg.
Number of subjects: 42
Study: 2278982

Group type: EXPERIMENTAL
Intervention: Inpatient family intervention (IFI) added to medication during the inpatient phase of treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatient family intervention (IFI)
Number of subjects: 0
Study: 7193668

Group type: EXPERIMENTAL
Intervention: Intravenous Dalacin C and Spectacilline for five days postoperatively
Number of subjects: 54

Group type: COMPARATOR
Intervention: Taurolin administered by intraperitoneal route
Number of subjects: 54
Study: 31792863

Group type: EXPERIMENTAL
Intervention: Intervention group received normal care plus HCV antibody tests ordered and customized messages sent through their tPHR inviting them to go directly to the lab for HCV screening over a 12-week period.
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Control group received normal care for HCV screening, consisting of passive HCV reminders to providers and passive HCV screening notification through the patient's tPHR.
Number of subjects: 1024
Study: 31190609

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily
Number of subjects: 420

Group type: COMPARATOR
Intervention: 40 mg of pravastatin daily
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Statin treatment (both atorvastatin and pravastatin)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 420
Study: 28931088

Group type: EXPERIMENTAL
Intervention: Integrated nutrition and health program
Number of subjects: 957

Group type: COMPARATOR
Intervention: Comparison district (Government of India's standard nutrition and health care program)
Number of subjects: 957
Study: 25579414

Group type: EXPERIMENTAL
Intervention: Active tDCS to visual cortex
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 23
Study: 23979564

Group type: EXPERIMENTAL
Intervention: Class III anti‐arrhythmic drugs at baseline
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Digitalis at baseline and 1 year
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Oral anti‐coagulation (OAC) without anti‐platelet drugs
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Drug conversions
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Electrical conversions
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Hospitalisations
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Strokes
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc scores
Number of subjects: 2742
Study: 21131556

Group type: EXPERIMENTAL
Intervention: BMS-641988 (daily doses escalated from 5 to 150 mg)
Number of subjects: 61
Study: 18608423

Group type: EXPERIMENTAL
Intervention: WOMAC pain score
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 15-m walk test
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Stairs up test
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Stairs down test
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: RPT extension of the affected side
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: RPT flexion of the affected side
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: RPT flexion of the contralateral side
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: RAND-36 Physical function (PF) score
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Comorbid diseases and pain
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Malalignments, restriction in flexion ROM, and radiologic severity of knee OA
Number of subjects: 88
Study: 16772904

Group type: EXPERIMENTAL
Intervention: Innervated flap (12 patients, 18 breasts)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Noninnervated flap (15 patients, 19 breasts)
Number of subjects: 27
Study: 15588464

Group type: EXPERIMENTAL
Intervention: Cetrorelix 3 mg on stimulation day 7 with r-hLH 150 IU on days 7-10 (n = 25)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cetrorelix 3 mg on stimulation day 7 without r-hLH on days 7-10 (n = 24)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Leuprolide acetate before ovarian stimulation with r-hFSH (n = 25)
Number of subjects: 74
Study: 11232016

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) and norethisterone enanthate (NETE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) alone
Number of subjects: 28
Study: 9207711

Group type: EXPERIMENTAL
Intervention: Young subjects (mean, 2.01 ± 0.46 degrees)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active elderly subjects (mean, 3.12 ± 1.12 degrees)
Number of subjects: 40
Study: 8480477

Group type: EXPERIMENTAL
Intervention: 1000 micrograms beclomethasone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 250 micrograms beclomethasone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3103044

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 12
Study: 29443445

Group type: EXPERIMENTAL
Intervention: Aspirin withdrawal
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28390213

Group type: EXPERIMENTAL
Intervention: Waterpik® Water Flosser (WF) plus manual tooth brushing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Interdental brushes (IDB) plus manual tooth brushing
Number of subjects: 28
Study: 24484241

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83